These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7063798)

  • 21. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
    Bailey CJ
    Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
    [No Abstract]   [Full Text] [Related]  

  • 22. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract]   [Full Text] [Related]  

  • 24. Fenofibric Acid (trilipix).
    Med Lett Drugs Ther; 2009 May; 51(1311):33-4. PubMed ID: 19417718
    [No Abstract]   [Full Text] [Related]  

  • 25. Fenofibrate for hypertriglyceridemia.
    Med Lett Drugs Ther; 1998 Jul; 40(1030):68-9. PubMed ID: 9664930
    [No Abstract]   [Full Text] [Related]  

  • 26. [Procetofen: hemolytic effect in subjects with G6PD deficiency. Description of a case].
    Testa S; Nurra P; Nurra V
    Clin Ter; 1982 Sep; 102(5):519-22. PubMed ID: 7151373
    [No Abstract]   [Full Text] [Related]  

  • 27. [Muscular involvement and fibrates. Analysis of databanks of the French System of Pharmacovigilance].
    Lavarenne J; Poinas-Caillaud H
    Therapie; 1991; 46(5):347-9. PubMed ID: 1754976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fenofibrate, a third-generation fibric acid derivative. Proceedings of a symposium. November 15, 1986, Dallas, Texas.
    Am J Med; 1987 Nov; 83(5B):1-89. PubMed ID: 3688010
    [No Abstract]   [Full Text] [Related]  

  • 29. Does Tricor cause gallstones?
    Lee T
    Harv Heart Lett; 2008 Jul; 18(11):8. PubMed ID: 18697244
    [No Abstract]   [Full Text] [Related]  

  • 30. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
    Magee G; Sharpe PC
    J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-lowering therapy--benefits and risks.
    Abinader EG
    Isr Med Assoc J; 2007 Feb; 9(2):132-3; author reply 133-4. PubMed ID: 17354321
    [No Abstract]   [Full Text] [Related]  

  • 32. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
    Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
    Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
    Hottelart C; el Esper N; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):41-4. PubMed ID: 10081035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
    Galiana J; Marchán E; Montés I; Pato S
    Rev Clin Esp; 1995 Sep; 195(9):620-2. PubMed ID: 7481005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
    Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
    J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fenofibrates and gynaecomastia].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2008 May; 135(5):437. PubMed ID: 18457741
    [No Abstract]   [Full Text] [Related]  

  • 37. [Increased CK in lipid-lowering therapy].
    Assmann G
    Internist (Berl); 1997 Nov; 38(11):1114. PubMed ID: 9453967
    [No Abstract]   [Full Text] [Related]  

  • 38. Intensive lipid-lowering therapy: obvious benefits, possible risks.
    Zimlichman E; Szyper-Kravitz M; Katz U; Shoenfeld Y
    Isr Med Assoc J; 2006 Dec; 8(12):890-1. PubMed ID: 17214117
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hepatic tolerance of procetofene].
    Rossi A
    Nouv Presse Med; 1978 Oct; 7(35):3153. PubMed ID: 724485
    [No Abstract]   [Full Text] [Related]  

  • 40. [Metabolism of fenofibrate and fenofibric acid in vivo and in cultures of liver epithelial cells (author's transl)].
    Dulery B; Hammami M; Chessebeuf M; Legendre M; Noly P; Padieu P; Maume BF
    Nouv Presse Med; 1980 Dec; 9(49):3729-32. PubMed ID: 7208338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.